Pharma & Biotech
BioNTech’s May Gauntlet: Earnings, a Shareholder Vote, and an Insider Sale Set the Stage
The first half of May is shaping up as a critical inflection point for BioNTech, with the German biotech facing...
Bayer’s €7 Billion Insurance Policy: Shareholders Back a Capital Cushion for the Glyphosate Endgame
Bayer’s annual general meeting on April 24 was a study in contradictions. Major institutional investors praised CEO Bill Anderson’s restructuring...
BioNTech’s Tightrope Walk: Can Pipeline Progress Bridge the Revenue Gap?
The narrative around BioNTech has shifted decisively. The pandemic-era cash cow is fading, and the company is now racing to...
Novo Nordisk’s Teen Pill Win Offers a Rebound, But the Washington Game Is Shifting
Novo Nordisk’s shares staged a dramatic recovery on Friday, surging nearly 7% to close at €35.16, as investors seized on...
Siemens Healthineers Faces a Perfect Storm as Basel Conference Opens Against a Backdrop of Debt and Declining Shares
The irony could hardly be starker. As Siemens Healthineers kicks off the ECIO oncology conference in Basel today, showcasing the...
Bayer’s Two-Front Battle: A Supreme Court Pivot and a €7 Billion War Chest
Bayer enters a defining week with its stock under pressure, a Supreme Court hearing on the horizon, and shareholders having...
BioNTech’s Insider Sale Doesn’t Deter Wall Street as Oncology Pipeline Takes Center Stage
The German biotech has clawed back more than 22 percent from its March nadir of €72.50, closing Friday at €88.75....
Eli Lilly’s Foundayo Stumbles Out of the Gate, Putting Pressure on Upcoming Earnings
Eli Lilly investors endured another bruising week as the pharmaceutical giant's stock slid nearly 5% on Friday, closing at €750....
ImmunityBio’s Record Revenue Overshadowed by FDA Fallout and Cash Burn
ImmunityBio is posting its strongest-ever quarterly sales, yet the stock is heading in the opposite direction. The biotech group generated...
Ocugen’s Analyst Consensus Is Unanimously Bullish — But the Charts Tell a Different Story
On paper, Ocugen has everything a small-cap biotech investor could want: seven buy ratings, zero holds or sells, and a...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
